Evidence map›Paper›PMID 33676649›Full record

ArticleTalanta2021

Development of a nanotechnology-based approach for capturing and detecting nucleic acids by using flow cytometry.

Agustín Robles-Remacho, M Angélica Luque-González, Roberto A González-Casín, M Victoria Cano-Cortés, F Javier Lopez-Delgado, Juan J Guardia-Monteagudo, Mario Antonio Fara, Rosario M Sánchez-Martín, Juan José Díaz-Mochón

Open access · greenAbstract read
In one paragraph

Article in Talanta, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.7field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 1 country.

Agustín Robles-RemachoGENYO. Centre for Genomics and Oncological Research: Pfizer / University of Granada / Andalusian Regional Government, PTS Granada, Avenida de La Ilustracion, 114, 18016, Granada, Spain; Department of Medicinal and Organic Chemistry, School of Pharmacy, University of Granada, Campus Cartuja S/n, 18071, Granada, Spain; Biosanitary Research Institute of Granada (ibs.GRANADA), University Hospital of Granada/University of Granada, Avenida Del Conocimiento, S/n, 18016, Granada, Spain.
M Angélica Luque-GonzálezGENYO. Centre for Genomics and Oncological Research: Pfizer / University of Granada / Andalusian Regional Government, PTS Granada, Avenida de La Ilustracion, 114, 18016, Granada, Spain; Department of Medicinal and Organic Chemistry, School of Pharmacy, University of Granada, Campus Cartuja S/n, 18071, Granada, Spain; Biosanitary Research Institute of Granada (ibs.GRANADA), University Hospital of Granada/University of Granada, Avenida Del Conocimiento, S/n, 18016, Granada, Spain.
Roberto A González-CasínGENYO. Centre for Genomics and Oncological Research: Pfizer / University of Granada / Andalusian Regional Government, PTS Granada, Avenida de La Ilustracion, 114, 18016, Granada, Spain.
M Victoria Cano-CortésGENYO. Centre for Genomics and Oncological Research: Pfizer / University of Granada / Andalusian Regional Government, PTS Granada, Avenida de La Ilustracion, 114, 18016, Granada, Spain; Department of Medicinal and Organic Chemistry, School of Pharmacy, University of Granada, Campus Cartuja S/n, 18071, Granada, Spain; Biosanitary Research Institute of Granada (ibs.GRANADA), University Hospital of Granada/University of Granada, Avenida Del Conocimiento, S/n, 18016, Granada, Spain.
F Javier Lopez-DelgadoDestiNA Genomica S.L, PTS Granada, Avenida de La Innovación 1, Edificio BIC, 18100, Armilla, Granada, Spain.
Juan J Guardia-MonteagudoDestiNA Genomica S.L, PTS Granada, Avenida de La Innovación 1, Edificio BIC, 18100, Armilla, Granada, Spain.
Mario Antonio FaraDestiNA Genomica S.L, PTS Granada, Avenida de La Innovación 1, Edificio BIC, 18100, Armilla, Granada, Spain.
Rosario M Sánchez-MartínGENYO. Centre for Genomics and Oncological Research: Pfizer / University of Granada / Andalusian Regional Government, PTS Granada, Avenida de La Ilustracion, 114, 18016, Granada, Spain; Department of Medicinal and Organic Chemistry, School of Pharmacy, University of Granada, Campus Cartuja S/n, 18071, Granada, Spain; Biosanitary Research Institute of Granada (ibs.GRANADA), University Hospital of Granada/University of Granada, Avenida Del Conocimiento, S/n, 18016, Granada, Spain. Electronic address: rmsanchez@go.ugr.es.
Juan José Díaz-MochónGENYO. Centre for Genomics and Oncological Research: Pfizer / University of Granada / Andalusian Regional Government, PTS Granada, Avenida de La Ilustracion, 114, 18016, Granada, Spain; Department of Medicinal and Organic Chemistry, School of Pharmacy, University of Granada, Campus Cartuja S/n, 18071, Granada, Spain; Biosanitary Research Institute of Granada (ibs.GRANADA), University Hospital of Granada/University of Granada, Avenida Del Conocimiento, S/n, 18016, Granada, Spain. Electronic address: juanjose.diaz@genyo.es.
Parque Tecnológico de la Salud · ESPfizer-University of Granada-Junta de Andalucía Centre for Genomics and Oncological Research · ESInstituto de Investigación Biosanitaria de Granada · ESUniversidad de Granada · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Nucleic acid-based molecular diagnosis has gained special importance for the detection and early diagnosis of genetic diseases as well as for the control of infectious disease outbreaks. The development of systems that allow for the detection and analysis of nucleic acids in a low-cost and easy-to-use way is of great importance. In this context, we present a combination of a nanotechnology-based approach with the already validated dynamic chemical labeling (DCL) technology, capable of reading nucleic acids with single-base resolution. This system allows for the detection of biotinylated molecular products followed by simple detection using a standard flow cytometer, a widely used platform in clinical and molecular laboratories, and therefore, is easy to implement. This proof-of-concept assay has been developed to detect mutations in KRAS codon 12, as these mutations are highly important in cancer development and cancer treatments.

Indexed as

Nucleic AcidsPeptide Nucleic AcidsFlow CytometryMutationNanotechnologyNucleic AcidsPeptide Nucleic AcidsDynamic chemical labeling (DCL)Fluorescence-activated cell sorting (FACS)KRAS point MutationNanotechnologyNucleic acid testing (NAT)Peptide nucleic acid (PNA)

Identifiers

PMID33676649
PMCPMC7794053
OpenAlexW3120191688

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.